Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  therapeutic allogeneic lymphocytes
Find trials that include:  Any drugs shown
Results 1-25 of 25 for your search:
Start Over
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Conventional and Regulatory T Cells in Treating Patients With Advanced Hematologic Malignancies Undergoing T Cell-Depleted Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 13 to 60
Trial IDs: BMT236, NCI-2011-03025, NCT01660607
Donor Natural Killer Cells in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 2 to 59
Trial IDs: 2012-0079, NCI-2014-00883, NCI-2014-00841, NCT01787474
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients with High Risk Myeloid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 2012-0819, NCI-2013-00993, RP110553-P3), NCT01823198
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 2 to 65
Trial IDs: 2012-0708, NCI-2013-02183, 05-07-04832, P01 - 5P01, RP110553 05-07-04832, NCT01904136
Alpha-Beta Depleted T-cells and Cyclophosphamide following Stem Cell Transplant in Treating Patients with Hematological Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 19 to 65
Trial IDs: UAB 1397, NCI-2015-01074, BMTCT-UAB 1397, NCI-2015-00289, NCT02193880
Donor Stem Cell Transplant and T-Cell Infusion with or without Low-Intensity Preparative Chemotherapy Using Sirolimus in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: 04-C-0055, NCI-2013-01407, 040055, 351967, NCI-2013-01404, NCT00077480, NCI-04-C-0055, NCT00074490
Reduced Intensity Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11D.247, NCI-2011-02345, 1795, 2011-31, NCT01384513
Risk-Directed Therapy in Treating Young Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: ALLR18, NCI-2012-00587, NCT01700946
Donor Progenitor Cell and Natural Kill Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: HAPNK1, NCI-2013-00609, NCT01807611
Donor T-cells after Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 14 to 75
Trial IDs: IRB12-1191, NCI-2013-00782, NCT01839916
Recombinant Human Interleukin-15 and Donor Natural Killer Cell Infusion in Treating Patients with Refractory or Relapsed Acute Myelogenous Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 9880, NCI-2015-00396, 2014LS092, P9880, NCT02395822
CD8+ Memory T-Cells as Consolidative Therapy after Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients with Leukemia or Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: IRB-33058 / BMT288, NCI-2015-00567, 33058, 351, BMT288, IRB-33058, NCT02424968
Microtransplantation in Treating Younger Patients with Refractory or Relapsed Hematological Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: MITREL, NCI-2015-00691, NCT02433483
Donor Cellular Therapy after Cytarabine in Treating Patients with Intermediate-Risk Acute Myeloid Leukemia in Remission
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 59 and under
Trial IDs: 9L-15-2, NCI-2015-01671, NCT02587871
Donor Stem Cell Transplant and Natural Killer Cells in Treating Patients With Advanced or Refractory Hematologic Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: IUCRO-0179, NCI-2011-02350, NCT00569179
Donor Natural Killer Cells and Monoclonal Antibody 3F8 after Combination Chemotherapy in Treating Patients with High-Risk Neuroblastoma
Status: Active
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: 09-011, NCI-2009-01378, MSKCC-09001, NCT00877110
INCB024360, Natural Killer Cells, and Aldesleukin after Preparative Chemotherapy in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012LS101, NCI-2014-00415, MT 2013-11, NCT02118285
Umbilical Cord Blood Transplant in Treating Young Patients With Hematologic Malignancies
Status: Active
Phase: No phase specified
Type: Treatment
Age: Children
Trial IDs: UCAML, NCI-2012-00795, H-26558, NCT01247701
Reduced-Intensity Conditioning before Donor Stem Cell Transplant in Treating Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 12D.501, NCI-2012-02762, 2012-67, NCT01760655
Donor Natural Killer Cell Infusion after Autologous CD133+ Selected Stem Cell Transplant in Treating Younger Patients with High Risk Solid Tumors or Lymphomas
Status: Active
Phase: No phase specified
Type: Treatment
Age: 21 and under
Trial IDs: ASCIST, NCI-2014-00275, NCT02130869
Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Temporarily closed
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14040, NCI-2014-01489, 2014C0146, NCT02316964
Laboratory-Treated Cord Blood-Derived T-cells in Preventing Graft-Versus-Host Disease in Patients with Hematologic Malignancies Undergoing Transplant
Status: Active
Phase: No phase specified
Type: Treatment
Age: 1 to 80
Trial IDs: 2014-0150, NCI-2015-00705, NCT02423915
Start Over